An Open-label, Observational 12-week Study to Assess Health-related Quality of Life and Patient-reported Outcomes in Patients With Rheumatoid Arthritis Treated With Certolizumab Pegol
Phase of Trial: Phase IV
Latest Information Update: 17 Oct 2015
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Acronyms SONAR-12
- Sponsors UCB Pharma SA
- 10 Jun 2017 Biomarkers information updated
- 14 Mar 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 12 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.